Sp360
DEBATE: TRADITIONAL VS ENDOSCOPIC APPROACH FOR THE DIAGNOSIS OF NAFLD
Date
May 7, 2023
Explore related products in the following collection:
Society: DDW
LIVE STREAM SESSION
LIVE STREAM SESSION
Presenters
Houston Methodist Hospital
Indiana University School of Medicine
Tracks
Related Products
IMMUNE EDITING IN THE INVASIVE MARGIN AND NODE DEPOSITS OF COLORECTAL CANCER SELECTS FOR CELLULAR NEIGHBOURHOODS ENRICHED IN PDL1+ CANCER CELLS
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
SINGLE-CELL INTESTINAL CHANGES IN PEDIATRIC CROHN'S DISEASE BEFORE AND AFTER ANTI-TNF BLOCKADE.
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
IL-17 SUPPRESSES PATHOGENESIS AND STEM CELL ACTIVATION WITHIN THE CONTEXT OF CHRONIC <i>HELICOBACTER PYLORI</i> INFECTION
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
MULTIMODAL SINGLE CELL ANALYSES REVEAL PATHOGENIC FIBROBLASTS IN PERIANAL FISTULA
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
